Share on StockTwits

Dr. Reddy's Laboratories Limited (NYSE:RDY) was upgraded by equities research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Thursday.

Dr. Reddy's Laboratories Limited (NYSE:RDY) traded up 0.85% during mid-day trading on Thursday, hitting $39.00. 107,757 shares of the company’s stock traded hands. Dr. Reddy's Laboratories Limited has a 1-year low of $31.32 and a 1-year high of $47.93. The stock’s 50-day moving average is $43.29 and its 200-day moving average is $42.35. The company has a market cap of $6.635 billion and a price-to-earnings ratio of 18.27.

Dr. Reddy's Laboratories Limited (NYSE:RDY) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $0.47 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.52 by $0.05. The company had revenue of $580.00 million for the quarter, compared to the consensus estimate of $557.00 million. Analysts expect that Dr. Reddy's Laboratories Limited will post $2.21 EPS for the current fiscal year.

RDY has been the subject of a number of other recent research reports. Analysts at TheStreet downgraded shares of Dr. Reddy's Laboratories Limited from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Separately, analysts at Morgan Stanley downgraded shares of Dr. Reddy's Laboratories Limited from an “overweight” rating to an “equal weight” rating in a research note on Wednesday, May 14th. Finally, analysts at Bank of America downgraded shares of Dr. Reddy's Laboratories Limited from a “buy” rating to an “underperform” rating in a research note on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $35.00.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) is an integrated global pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.